Cytokine gene polymorphism in sympathetic ophthalmia

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 11, 2005, Pages 4245-4250

  Atan, Denize ^a   Turner, Steve J ^a   Kilmartin, Dara J ^b   Forrester, John V ^c   Bidwell, Jeff ^d   Dick, Andrew D ^a   Churchill, Amanda J ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA EYE AND EAR HOSPITAL   (Ireland)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; LYMPHOTOXIN; MONOCLONAL ANTIBODY; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; PRIMER DNA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; IMMUNOGENETICS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC OPHTHALMIA; UNITED KINGDOM; AGAR GEL ELECTROPHORESIS; CHEMISTRY; GENE FREQUENCY; GENETIC MARKER; GENETICS; GENOTYPE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CYTOKINES; DNA PRIMERS; ELECTROPHORESIS, AGAR GEL; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HUMANS; INTERLEUKIN-10; LYMPHOTOXIN-ALPHA; MALE; OPHTHALMIA, SYMPATHETIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644693853     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0126     Document Type: Article

References (43)

1. Nussenblatt RB, Palestine AB, Whitcup SM, Craven L. Sympathetic Ophthalmia. In Uveitis: Fundamentals and Clinical Practice. St Louis, MO: CV Mosby; 1995;299-311.
2. Rao NA, Robin J, Hartman D, Sweeney JA, Marak GE Jr. The role of the penetrating wound in the development of sympathetic ophthalmia: experimental observations. Arch Ophthalmol. 1983;101:102-104.
3. Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338:1498-1501.
4. Liversidge J, Dick A, Cheng YF, Scott GB, Forrester JV. Retinal antigen specific lymphocytes, TCR-gamma delta cells and CD5+ B cells cultured from the vitreous in acute sympathetic ophthalmitis. Autoimmunity. 1993;15:257-266.
5. Kilmartin DJ, Dick AD, Forrester JV. Prospective surveillance of sympathetic ophthalmia in the UK and Republic of Ireland. Br J Ophthalmol. 2000;84:259-263.
6. Kilmartin DJ, Wilson D, Liversidge J, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br J Ophthalmol. 2000;85:281-286.
7. Davey MP, Rosenbaum JT. The human leukocyte antigen complex and chronic ocular inflammatory disorders. Am J Ophthalmol. 2000:129:235-243.
8. Allahabadia A, Heward JM, Nithiyananthan R, et al. MHC class II region, CTLA-4 gene, and ophthalmopathy in patients with Graves' disease. Lancet. 2001;358:984-985.
9. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumour necrosis factor receptor 2 (TNFR2) polymorphism with susceptibility to systemic lupus erythematosus. Tissue Antigens. 1999;53:527-533.
10. Hulkkonen J, Pertovaara M, Antonen J, Lahdenpohia N, Paternak A, Hurme M. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren's syndrome. Arthritis Rheum. 2001;44:176-179.
11. Verity DH, Wallace GR, Vaughan RW, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens. 1999;54:264-272.
12. Pociot F, Briant L, Jongeneel CV, et al. Association of tumour factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. J Immunol. 1993;23:224-231.
13. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumour necrosis factor alpha promoter on transcriptlonal activation. Proc Natl Acad Sci USA. 1997;94:3195-3199.
14. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
15. Hakin KN, Pearson RV, Lightman SL. Sympathetic ophthalmia: visual results with modern immunosuppressive therapy. Eye. 1992;6:453-455.
16. Chan CC, Roberge RG, Whitcup SM, Nussenblatt RB. 32 cases of sympathetic ophthalmia: a retrospective study at the National Eye Institute, Bethesda, Md., from 1982 to 1992. Arch Ophthalmol. 1995;113:597-600.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
18. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992;39:225-235.
19. Al-Ansari AS, Ollier WE, Villarreal J, Ordi J, The LS, Hajeer AH. Tumour necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens. 2000;55:97-99.
20. Heward JM, Allahabadia A, Armitage M, et al. The development of Graves' disease and the CTLA-4 gene on chromosome 2q33. J Clin Endocrinol Metab. 1999;84:2398-2401.
21. Svejgaard A, Ryder LP. HLA and disease associations: detecting the strongest association. Tissue Antigens. 1994;43:18-27.
22. BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P. Uveitis Scoring System. Berlin, Germany: Springer Verlag; 1991.
23. Cope AP. Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology. 2003;42:716-731.
24. Lombardi G, Dunne PJ, Scheel-Toellner D, et al. Type I IFN maintains the survival of anergic CD4+ T cells. J Immunol. 2000;165:3782-3789.
25. Salmon M, Scheel-Toellner D, Huissoon AP, et al. Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest. 1997;99:439-446.
26. Sun B, Sun SH, Chan CC, Caspi RR. Evaluation of in vivo cytokine expression in EAU-susceptible and resistant rats: a role for IL-10 in resistance? Exp Eye Res. 2000;70:493-502.
27. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991;146:3444-3451.
28. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915-924.
29. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996;184:19-29.
30. Rizzo LV, Morawetz RA, Miller-Rivero NE, et al. IL-4 and IL-10 are both required for the induction of oral tolerance. J Immunol. 1999;162:26l3-2622.
31. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-1108.
32. de Kozak Y, Cotinet A, Goureau O, Hicks D, Thillaye-Goldenberg B. Tumour necrosis factor and nitric oxide production by resident glial cells from rats presenting hereditary retinal degeneration. Ocul Immunol Inflamm. 1997;5:85-94.
33. de Kozak Y, Naud MC, Bellot J, Faure JP, Hicks D. Differential tumour necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant strains. J Neuroimmunol. 1994;55:1-9.
34. Dick AD, McMenamin PG, Korner H, et al. Inhibition of tumour necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur J Immunol. 1996;26:1018-1025.
35. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumour necrosis factor-alpha in the induction of experimental uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35):3884-3889.
36. Cope AP, Iiblau RS, Yang XD, et al. Chronic tumour necrosis factor alters T cell responses by attenuating T cell receptor signalling. J Exp Med. 1997;185:1573-1584.
37. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348-351.
38. Kawasaki A, Tsuchiya N, Hagiwara K, Takazoe M, Tokunaga K. Independent contribution of HLA-DRB1 and TNFalpha promoter polymorphisms to the susceptibility to Crohn's disease. Genes Immunol. 2000;1:351-357.
39. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA. 1997;94:8093-8098.
40. Brito BE, O'Rourke LM, Pan Y, Anglin J, Planck SR, Rosenbaum JT. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci. 1999;40:2583-2589.
41. Verwaerde C, Naud MC, Delanoye A, et al. Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther. 2003;10:1970-1981.
42. Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci. 2004;45:170-176.
43. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 2004;50:1077-1082.